Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines

Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint pathways has led to a rapidly expanding repertoire of immune checkpoint inhibitors for the treatment of various cancers. The app...

Full description

Bibliographic Details
Main Authors: Saralinh Trinh, Alex Le, Sajida Gowani, Ninh M La-Beck
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Asia-Pacific Journal of Oncology Nursing
Subjects:
Adverse events
atezolizumab
durvalumab
immune checkpoint
ipilimumab
management
nivolumab
pembrolizumab
side effects
toxicity
Online Access:http://www.apjon.org/article.asp?issn=2347-5625;year=2019;volume=6;issue=2;spage=154;epage=160;aulast=Trinh

Internet

http://www.apjon.org/article.asp?issn=2347-5625;year=2019;volume=6;issue=2;spage=154;epage=160;aulast=Trinh

Similar Items